UNITE®
Where LAMP-vax once existed in relative isolation, ITI’s core technology has expanded to include an array of helpful tools which have the potential to substantially expand and amplify the immune response. In synchrony with the next-generation of lysosomal targeting, the selection and optimization of antigens, combination of adjuvants and optimal use of various delivery methods have provided a means by which ITI’s technology can best approach the challenges ahead.
UNITE®: ‘UNiversal Intracellular Targeted Expression’
UNITE® correctly describes what ITI has built over the past decade. We have moved past simply using the original design of LAMP for intracellular targeting; UNITE® is an acronym for UNiversal Intracellular Targeted Expression and describes a combination of intracellular and molecular biology methods for enhanced MHC-II presentation combined with potent adjuvant and delivery technologies that result in a unified and complete immune system response.
– Teri Heiland, CSO
Since the early use of LAMP-vax in 2006, a number of important advances in related and complementary fields have occurred. When combined with the development of the Company’s lysosomal targeting vaccine, these technologies form a comprehensive platform solution.
LAMP-vax (2006 – 2012)
Lysosomal Targeting
- LAMP / Luminal LAMP
- Basic vector construction
No Adjuvants
- DNA delivered in PBS
Delivery Methods
- Needle & syringe
Small Scale Manufacturing
- cGMP, < 10g
UNITE® Technology (Current)
Lysosomal Targeting
- 3rd generation targeting developed by ITI
- Advanced vector design
- pNDA, mRNA, and other designs available
Adjuvants
- Options to enhance immune response include cytokines & tetanus toxin
Delivery Methods
- Optimized for ID delivery
- Electroporation available
Large Scale Manufacturing
- cGMP, up to 300g
LAMP-vax (2006 – 2012)
Lysosomal Targeting
- LAMP / Luminal LAMP
- Basic vector construction
No Adjuvants
- DNA delivered in PBS
Delivery Methods
- Needle & syringe
Small Scale Manufacturing
- cGMP, < 10g
UNITE® Technology (Current)
Lysosomal Targeting
- 3rd generation targeting developed by ITI
- Advanced vector design
- pNDA, mRNA, and other designs available
Adjuvants
- Options to enhance immune response include cytokines & tetanus toxin
Delivery Methods
- Optimized for ID delivery
- Electroporation available
Large Scale Manufacturing
- cGMP, up to 300g